Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1 ...
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...
TD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TD Cowen analyst Daniel Brennan maintained a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of ...
Myriad Genetics comments on UnitedHealthcare’s updated policy
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...
bovnews1d
The Myriad Genetics, Inc. Rollercoaster: What’s Behind the Latest MYGN Stock Fluctuation?
On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...
Nasdaq4d
Myriad Genetics Enters Oversold Territory (MYGN)
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Myriad Genetics, Inc. (Symbol: MYGN) entered into oversold territory, hitting an RSI reading ...
Nasdaq8d
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
Myriad Genetics (MYGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...